09/2019
FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study
(Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)
Read More